Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BRAIN Biotech AG's shares outstanding for the quarter that ended in Mar. 2026 was 21.85 Mil.
BRAIN Biotech AG's quarterly shares outstanding
stayed the same
from Dec. 2025 (21.85 Mil) to Mar. 2026 (21.85 Mil).
BRAIN Biotech AG's annual shares outstanding
stayed the same
from Sep. 2024 (21.85 Mil) to Sep. 2025 (21.85 Mil).
BRAIN Biotech AG (HAM:BNN) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
BRAIN Biotech AG Shares Outstanding (EOP) Related Terms
BRAIN Biotech AG Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: Shares Outstanding (EOP) Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Shares Outstanding (EOP) vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Shares Outstanding (EOP) falls into.
BRAIN Biotech AG Shares Outstanding (EOP) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 21.85 Mil mean?
BRAIN Biotech AG (HAM:BNN) has a Shares Outstanding (EOP) of 21.85 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Shares Outstanding (EOP) too high?
BRAIN Biotech AG's current Shares Outstanding (EOP) is 21.85 Mil. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Shares Outstanding (EOP) compare to LIN and SHW?
BRAIN Biotech AG's Shares Outstanding (EOP) of 21.85 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Chemicals company?
A good Shares Outstanding (EOP) depends on the Chemicals industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Shares Outstanding (EOP) is 21.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.48, compared to a current price of €2.86 — trading 15.3% above its estimated fair value. The current Shares Outstanding (EOP) is 21.85 Mil. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Shares Outstanding (EOP) is 21.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.86 is trading 15.3% above its estimated GF Value™ of €2.48.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
Shares Outstanding (EOP): 21.85 Mil
GF Value™: €2.48 vs. price of €2.86 (15.3% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
